SCHEMBL15042833

SCHEMBL15042833

CC(C)c1cc2ccc3cccc(C(C)C)c3c2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN2 Q9H2S1 5/20 0.38
KCNN3 Q9UGI6 5/20 0.38
TSHR P16473 3/20 0.34
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 3/20 0.34
HPGD P15428 2/20 0.34
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
HTR2C P28335 2/20 0.34
HTR2B P41595 2/20 0.34
LMNA P02545 2/20 0.34
FAAH O00519 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
GABRB1 P18505 1/20 0.34
PTGS1 P23219 1/20 0.34
SLC6A2 P23975 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17811226 0.86 DAO (0.40) KCNN2KCNN3TSHRCYP1A2CYP3A4
SCHEMBL15042825 0.79 LMNA (0.36) TSHRCYP1A2CYP3A4HPGDGABRA1
SCHEMBL15042856 0.78 EIF4A3 (0.36) TSHRCYP1A2LMNAEIF4A3DAO
SCHEMBL15042892 0.78 DHFR (0.49) KCNN2KCNN3TSHRCYP1A2CYP3A4
SCHEMBL16380981 0.75 DAO (0.50) CYP1A2HPGDDAOALDH1A1HSD17B10
SCHEMBL23676472 0.74 DAO (0.49) CYP1A2CYP3A4DAOMEN1KMT2A
SCHEMBL16380961 0.74 DAO (0.49) EIF4A3DAOUGT2B7
SCHEMBL9170583 0.73 GABRA1 (0.52) KCNN2KCNN3TSHRCYP1A2CYP3A4
SCHEMBL25787433 0.71 ITK (0.45) TSHRHPGDLMNABLMDAO
SCHEMBL15912344 0.71 KIF11 (0.41) TSHRGABRA1LMNACA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS SCHERING CORPORATION 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS HAVCR2, ELOC, ZC3HAV1 KCNN2 4772/4885KCNN3 4662/4885TSHR 3711/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L KCNN2 4752/4885KCNN3 4737/4885TSHR 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.